Global Acute Coronary Syndrome Market to Reach $17.6 Billion by 2030
The global market for Acute Coronary Syndrome estimated at US$7.9 Billion in the year 2022, is projected to reach a revised size of US$17.6 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2022-2030.The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 16.6% CAGR
The Acute Coronary Syndrome market in the U.S. is estimated at US$2.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 10.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR.Select Competitors (Total 62 Featured) -
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Biological E. Ltd.
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Johnson & Johnson
- Momenta Pharmaceuticals, Inc.
- Pfizer, Inc.
- Recordati SpA
- The Medicines Company
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Biological E. Ltd.
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Johnson & Johnson
- Momenta Pharmaceuticals, Inc.
- Pfizer, Inc.
- Recordati SpA
- The Medicines Company
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 182 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 7.9 Billion |
Forecasted Market Value ( USD | $ 17.6 Billion |
Compound Annual Growth Rate | 10.5% |
Regions Covered | Global |